Roles of lysophosphatidic acid in cardiovascular physiology and disease
- PMID: 18586114
- PMCID: PMC2572771
- DOI: 10.1016/j.bbalip.2008.05.008
Roles of lysophosphatidic acid in cardiovascular physiology and disease
Abstract
The bioactive lipid mediator lysophosphatidic acid (LPA) exerts a range of effects on the cardiovasculature that suggest a role in a variety of critical cardiovascular functions and clinically important cardiovascular diseases. LPA is an activator of platelets from a majority of human donors identifying a possible role as a regulator of acute thrombosis and platelet function in atherogenesis and vascular injury responses. Of particular interest in this context, LPA is an effective phenotypic modulator of vascular smooth muscle cells promoting the de-differentiation, proliferation and migration of these cells that are required for the development of intimal hyperplasia. Exogenous administration of LPA results in acute and systemic changes in blood pressure in different animal species, suggesting a role for LPA in both normal blood pressure regulation and hypertension. Advances in our understanding of the molecular machinery responsible for the synthesis, actions and inactivation of LPA now promise to provide the tools required to define the role of LPA in cardiovascular physiology and disease. In this review we discuss aspects of LPA signaling in the cardiovasculature focusing on recent advances and attempting to highlight presently unresolved issues and promising avenues for further investigation.
Similar articles
-
Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity.J Biol Chem. 2003 Oct 31;278(44):43214-23. doi: 10.1074/jbc.M306709200. Epub 2003 Aug 8. J Biol Chem. 2003. PMID: 12909631
-
Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure.Circ Res. 2008 Sep 12;103(6):662-70. doi: 10.1161/CIRCRESAHA.108.180778. Epub 2008 Aug 14. Circ Res. 2008. PMID: 18703779 Free PMC article.
-
Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases.Biochem Pharmacol. 2019 Jun;164:74-81. doi: 10.1016/j.bcp.2019.03.035. Epub 2019 Mar 27. Biochem Pharmacol. 2019. PMID: 30928673 Review.
-
Roles for lysophosphatidic acid signaling in vascular development and disease.Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Aug;1865(8):158734. doi: 10.1016/j.bbalip.2020.158734. Epub 2020 May 3. Biochim Biophys Acta Mol Cell Biol Lipids. 2020. PMID: 32376340 Review.
-
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis.J Biol Chem. 2009 Mar 13;284(11):7385-94. doi: 10.1074/jbc.M807820200. Epub 2009 Jan 12. J Biol Chem. 2009. PMID: 19139100 Free PMC article.
Cited by
-
Synergistic Effect of WTC-Particulate Matter and Lysophosphatidic Acid Exposure and the Role of RAGE: In-Vitro and Translational Assessment.Int J Environ Res Public Health. 2020 Jun 17;17(12):4318. doi: 10.3390/ijerph17124318. Int J Environ Res Public Health. 2020. PMID: 32560330 Free PMC article.
-
Hypothalamic and ovarian transcriptome profiling reveals potential candidate genes in low and high egg production of white Muscovy ducks (Cairina moschata).Poult Sci. 2021 Sep;100(9):101310. doi: 10.1016/j.psj.2021.101310. Epub 2021 Jun 6. Poult Sci. 2021. PMID: 34298381 Free PMC article.
-
Lysophospholipid receptors in vertebrate development, physiology, and pathology.J Lipid Res. 2009 Apr;50 Suppl(Suppl):S293-8. doi: 10.1194/jlr.R800047-JLR200. Epub 2008 Dec 8. J Lipid Res. 2009. PMID: 19065000 Free PMC article. Review.
-
Lysophosphatidic acid enhances neointimal hyperplasia following vascular injury through modulating proliferation, autophagy, inflammation and oxidative stress.Mol Med Rep. 2018 Jul;18(1):87-96. doi: 10.3892/mmr.2018.8937. Epub 2018 Apr 27. Mol Med Rep. 2018. PMID: 29749484 Free PMC article.
-
Autotaxin in Breast Cancer: Role, Epigenetic Regulation and Clinical Implications.Cancers (Basel). 2022 Nov 4;14(21):5437. doi: 10.3390/cancers14215437. Cancers (Basel). 2022. PMID: 36358855 Free PMC article. Review.
References
-
- Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood. 2004;104:1361–1368. - PubMed
-
- Alexander JS, Patton WF, Christman BW, Cuiper LL, Haselton FR. Platelet-derived lysophosphatidic acid decreases endothelial permeability in vitro. Am J Physiol. 1998;274:H115–H122. - PubMed
-
- Amisten S, Braun OO, Bengtsson A, Erlinge D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res. 2007;122:47–57. - PubMed
-
- Aoki J. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol. 2004;15:477–489. - PubMed
-
- Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi R, Arai H. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem. 2002;277:48737–48744. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous